MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.
Identifieur interne : 003910 ( PubMed/Corpus ); précédent : 003909; suivant : 003911MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.
Auteurs : Matthias S. Dettmer ; Aurel Perren ; Holger Moch ; Paul Komminoth ; Yuri E. Nikiforov ; Marina N. NikiforovaSource :
- Journal of molecular endocrinology [ 1479-6813 ] ; 2014.
English descriptors
- KwdEn :
- Cell Differentiation (genetics), Cluster Analysis, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Male, MicroRNAs (genetics), MicroRNAs (metabolism), Middle Aged, Prognosis, Thyroid Neoplasms (diagnosis), Thyroid Neoplasms (genetics), Thyroid Neoplasms (pathology).
- MESH :
- chemical , genetics : MicroRNAs.
- diagnosis : Thyroid Neoplasms.
- genetics : Cell Differentiation, Thyroid Neoplasms.
- chemical , metabolism : MicroRNAs.
- pathology : Thyroid Neoplasms.
- Cluster Analysis, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis.
Abstract
The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas is difficult. The aim of this study is to characterise their largely unknown miRNA expression profile and to compare it with well-differentiated thyroid tumours, as well as to identify miRNAs which could potentially serve as diagnostic and prognostic markers. A total of 14 poorly differentiated (PD), 13 oPD, 72 well-differentiated thyroid carcinomas and eight normal thyroid specimens were studied for the expression of 768 miRNAs using PCR-Microarrays. MiRNA expression was different between PD and oPD thyroid carcinomas, demonstrating individual clusters on the clustering analysis. Both tumour types showed upregulation of miR-125a-5p, -15a-3p, -182, -183-3p, -222, -222-5p, and downregulation of miR-130b, -139-5p, -150, -193a-5p, -219-5p, -23b, -451, -455-3p and of miR-886-3p as compared with normal thyroid tissue. In addition, the oPD thyroid carcinomas demonstrated upregulation of miR-221 and miR-885-5p. The difference in expression was also observed between miRNA expression in PD and well-differentiated tumours. The CHAID algorithm allowed the separation of PD from well-differentiated thyroid carcinomas with 73-79% accuracy using miR-23b and miR-150 as a separator. Kaplan-Meier and multivariate analysis showed a significant association with tumour relapses (for miR-23b) and with tumour-specific death (for miR-150) in PD and oPD thyroid carcinomas. MiRNA expression is different in conventional and oPD thyroid carcinomas in comparison with well-differentiated thyroid cancers and can be used for discrimination between these tumour types. The newly identified deregulated miRNAs (miR-150, miR-23b) bear the potential to be used in a clinical setting, delivering prognostic and diagnostic informations.
DOI: 10.1530/JME-13-0266
PubMed: 24443580
Links to Exploration step
pubmed:24443580Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.</title><author><name sortKey="Dettmer, Matthias S" sort="Dettmer, Matthias S" uniqKey="Dettmer M" first="Matthias S" last="Dettmer">Matthias S. Dettmer</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern, Switzerland Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland Institute of Surgical Pathology, Triemlispital Zurich, 8063 Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Perren, Aurel" sort="Perren, Aurel" uniqKey="Perren A" first="Aurel" last="Perren">Aurel Perren</name></author><author><name sortKey="Moch, Holger" sort="Moch, Holger" uniqKey="Moch H" first="Holger" last="Moch">Holger Moch</name></author><author><name sortKey="Komminoth, Paul" sort="Komminoth, Paul" uniqKey="Komminoth P" first="Paul" last="Komminoth">Paul Komminoth</name></author><author><name sortKey="Nikiforov, Yuri E" sort="Nikiforov, Yuri E" uniqKey="Nikiforov Y" first="Yuri E" last="Nikiforov">Yuri E. Nikiforov</name></author><author><name sortKey="Nikiforova, Marina N" sort="Nikiforova, Marina N" uniqKey="Nikiforova M" first="Marina N" last="Nikiforova">Marina N. Nikiforova</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24443580</idno><idno type="pmid">24443580</idno><idno type="doi">10.1530/JME-13-0266</idno><idno type="wicri:Area/PubMed/Corpus">003910</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003910</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.</title><author><name sortKey="Dettmer, Matthias S" sort="Dettmer, Matthias S" uniqKey="Dettmer M" first="Matthias S" last="Dettmer">Matthias S. Dettmer</name><affiliation><nlm:affiliation>Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern, Switzerland Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland Institute of Surgical Pathology, Triemlispital Zurich, 8063 Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Perren, Aurel" sort="Perren, Aurel" uniqKey="Perren A" first="Aurel" last="Perren">Aurel Perren</name></author><author><name sortKey="Moch, Holger" sort="Moch, Holger" uniqKey="Moch H" first="Holger" last="Moch">Holger Moch</name></author><author><name sortKey="Komminoth, Paul" sort="Komminoth, Paul" uniqKey="Komminoth P" first="Paul" last="Komminoth">Paul Komminoth</name></author><author><name sortKey="Nikiforov, Yuri E" sort="Nikiforov, Yuri E" uniqKey="Nikiforov Y" first="Yuri E" last="Nikiforov">Yuri E. Nikiforov</name></author><author><name sortKey="Nikiforova, Marina N" sort="Nikiforova, Marina N" uniqKey="Nikiforova M" first="Marina N" last="Nikiforova">Marina N. Nikiforova</name></author></analytic><series><title level="j">Journal of molecular endocrinology</title><idno type="eISSN">1479-6813</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cell Differentiation (genetics)</term><term>Cluster Analysis</term><term>Female</term><term>Gene Expression Profiling</term><term>Gene Expression Regulation, Neoplastic</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>MicroRNAs (genetics)</term><term>MicroRNAs (metabolism)</term><term>Middle Aged</term><term>Prognosis</term><term>Thyroid Neoplasms (diagnosis)</term><term>Thyroid Neoplasms (genetics)</term><term>Thyroid Neoplasms (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>MicroRNAs</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Cell Differentiation</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>MicroRNAs</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cluster Analysis</term><term>Female</term><term>Gene Expression Profiling</term><term>Gene Expression Regulation, Neoplastic</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas is difficult. The aim of this study is to characterise their largely unknown miRNA expression profile and to compare it with well-differentiated thyroid tumours, as well as to identify miRNAs which could potentially serve as diagnostic and prognostic markers. A total of 14 poorly differentiated (PD), 13 oPD, 72 well-differentiated thyroid carcinomas and eight normal thyroid specimens were studied for the expression of 768 miRNAs using PCR-Microarrays. MiRNA expression was different between PD and oPD thyroid carcinomas, demonstrating individual clusters on the clustering analysis. Both tumour types showed upregulation of miR-125a-5p, -15a-3p, -182, -183-3p, -222, -222-5p, and downregulation of miR-130b, -139-5p, -150, -193a-5p, -219-5p, -23b, -451, -455-3p and of miR-886-3p as compared with normal thyroid tissue. In addition, the oPD thyroid carcinomas demonstrated upregulation of miR-221 and miR-885-5p. The difference in expression was also observed between miRNA expression in PD and well-differentiated tumours. The CHAID algorithm allowed the separation of PD from well-differentiated thyroid carcinomas with 73-79% accuracy using miR-23b and miR-150 as a separator. Kaplan-Meier and multivariate analysis showed a significant association with tumour relapses (for miR-23b) and with tumour-specific death (for miR-150) in PD and oPD thyroid carcinomas. MiRNA expression is different in conventional and oPD thyroid carcinomas in comparison with well-differentiated thyroid cancers and can be used for discrimination between these tumour types. The newly identified deregulated miRNAs (miR-150, miR-23b) bear the potential to be used in a clinical setting, delivering prognostic and diagnostic informations.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24443580</PMID><DateCreated><Year>2014</Year><Month>03</Month><Day>07</Day></DateCreated><DateCompleted><Year>2014</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1479-6813</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of molecular endocrinology</Title><ISOAbbreviation>J. Mol. Endocrinol.</ISOAbbreviation></Journal><ArticleTitle>MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.</ArticleTitle><Pagination><MedlinePgn>181-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1530/JME-13-0266</ELocationID><Abstract><AbstractText>The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas is difficult. The aim of this study is to characterise their largely unknown miRNA expression profile and to compare it with well-differentiated thyroid tumours, as well as to identify miRNAs which could potentially serve as diagnostic and prognostic markers. A total of 14 poorly differentiated (PD), 13 oPD, 72 well-differentiated thyroid carcinomas and eight normal thyroid specimens were studied for the expression of 768 miRNAs using PCR-Microarrays. MiRNA expression was different between PD and oPD thyroid carcinomas, demonstrating individual clusters on the clustering analysis. Both tumour types showed upregulation of miR-125a-5p, -15a-3p, -182, -183-3p, -222, -222-5p, and downregulation of miR-130b, -139-5p, -150, -193a-5p, -219-5p, -23b, -451, -455-3p and of miR-886-3p as compared with normal thyroid tissue. In addition, the oPD thyroid carcinomas demonstrated upregulation of miR-221 and miR-885-5p. The difference in expression was also observed between miRNA expression in PD and well-differentiated tumours. The CHAID algorithm allowed the separation of PD from well-differentiated thyroid carcinomas with 73-79% accuracy using miR-23b and miR-150 as a separator. Kaplan-Meier and multivariate analysis showed a significant association with tumour relapses (for miR-23b) and with tumour-specific death (for miR-150) in PD and oPD thyroid carcinomas. MiRNA expression is different in conventional and oPD thyroid carcinomas in comparison with well-differentiated thyroid cancers and can be used for discrimination between these tumour types. The newly identified deregulated miRNAs (miR-150, miR-23b) bear the potential to be used in a clinical setting, delivering prognostic and diagnostic informations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dettmer</LastName><ForeName>Matthias S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA Institute of Pathology, University of Bern, Murtenstrasse 31, 3010 Bern, Switzerland Institute of Surgical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland Institute of Surgical Pathology, Triemlispital Zurich, 8063 Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perren</LastName><ForeName>Aurel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Moch</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Komminoth</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nikiforov</LastName><ForeName>Yuri E</ForeName><Initials>YE</Initials></Author><Author ValidYN="Y"><LastName>Nikiforova</LastName><ForeName>Marina N</ForeName><Initials>MN</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA088041</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA88041</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Mol Endocrinol</MedlineTA><NlmUniqueID>8902617</NlmUniqueID><ISSNLinking>0952-5041</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80</RefSource><PMID Version="1">16365291</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Genomics. 2011 Dec;12(8):609-17</RefSource><PMID Version="1">22654560</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 1986 Nov;63(5):1170-3</RefSource><PMID Version="1">3760117</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods. 2001 Dec;25(4):402-8</RefSource><PMID Version="1">11846609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2013 Apr 30;108(8):1659-67</RefSource><PMID Version="1">23538390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Sci. 2013 Jan;104(1):48-54</RefSource><PMID Version="1">23013135</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Relat Cancer. 2007 Sep;14(3):791-8</RefSource><PMID Version="1">17914108</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Jun 1;69(11):4885-93</RefSource><PMID Version="1">19487299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Thyroid. 2013 Nov;23(11):1383-9</RefSource><PMID Version="1">23427895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Pathol. 2011 Dec;22(4):190-4</RefSource><PMID Version="1">21969055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Pathol. 2008 Fall;19(3):150-5</RefSource><PMID Version="1">18766471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Jun 9;435(7043):834-8</RefSource><PMID Version="1">15944708</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2009 Apr 9;458(7239):762-5</RefSource><PMID Version="1">19219026</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2012 Apr 1;18(7):2032-8</RefSource><PMID Version="1">22351693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer J. 2012 May-Jun;18(3):238-43</RefSource><PMID Version="1">22647360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Horm Metab Res. 2009 Jun;41(6):475-81</RefSource><PMID Version="1">19370508</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41</RefSource><PMID Version="1">19837916</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg Pathol. 2011 Dec;35(12):1866-72</RefSource><PMID Version="1">21989341</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 1993 Dec 3;75(5):843-54</RefSource><PMID Version="1">8252621</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2010 Jan 19;102(2):376-82</RefSource><PMID Version="1">20029416</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Pathol. 2007 Fall;18(3):163-73</RefSource><PMID Version="1">18058265</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg Pathol. 2007 Aug;31(8):1256-64</RefSource><PMID Version="1">17667551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mod Pathol. 2008 Sep;21(9):1139-46</RefSource><PMID Version="1">18587330</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2005 Aug;41(12):1690-6</RefSource><PMID Version="1">16043346</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2004 Jan 23;116(2):281-97</RefSource><PMID Version="1">14744438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2011 Jul;18(7):2035-41</RefSource><PMID Version="1">21537871</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Pathol. 2009 Nov;62(11):978-85</RefSource><PMID Version="1">19625289</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1983 Nov 15;52(10):1849-55</RefSource><PMID Version="1">6313176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2009 Jun 12;137(6):1005-17</RefSource><PMID Version="1">19524505</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2013 Jan;98(1):E1-7</RefSource><PMID Version="1">23150679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Histopathology. 2012 Jun;60(7):1045-51</RefSource><PMID Version="1">22348590</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg Pathol. 1984 Sep;8(9):655-68</RefSource><PMID Version="1">6476195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2008 May;93(5):1600-8</RefSource><PMID Version="1">18270258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Pathol. 2010 Mar;21(1):1-6</RefSource><PMID Version="1">19960273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Endocr Pathol. 2009 Summer;20(2):85-91</RefSource><PMID Version="1">19352602</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Endocrinol Metab. 2012 Sep;97(9):3292-301</RefSource><PMID Version="1">22730517</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS558987</OtherID><OtherID Source="NLM">PMC4010646</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">follicular thyroid carcinoma</Keyword><Keyword MajorTopicYN="N">miRNA profiling</Keyword><Keyword MajorTopicYN="N">papillary carcinoma</Keyword><Keyword MajorTopicYN="N">poorly differentiated carcinoma</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword><Keyword MajorTopicYN="N">thyroid cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24443580</ArticleId><ArticleId IdType="pii">JME-13-0266</ArticleId><ArticleId IdType="doi">10.1530/JME-13-0266</ArticleId><ArticleId IdType="pmc">PMC4010646</ArticleId><ArticleId IdType="mid">NIHMS558987</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003910 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003910 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24443580
|texte= MicroRNA profile of poorly differentiated thyroid carcinomas: new diagnostic and prognostic insights.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24443580" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |